Showing posts with label steroid therapy. Show all posts
Showing posts with label steroid therapy. Show all posts

Tuesday, 1 June 2010

Steroid therapies can be avoided after transplant

The use of modern immunosuppressive drugs can help in maintaining kidney function along with eliminating the need for steroid therapy as early as one week following a transplant surgery.
It was remarked by Steve Woodle, MD, chief of UC’s transplant surgery division, principal investigator and designer of the study that eliminating a daily dose of steroids after a transplant minimizes chronic health conditions that are common to kidney transplant recipients.
Steroids have long been the primary source of morbidity and complications following successful kidney transplantation,” Woodle says. “This study demonstrates that elimination of even small, daily prednisone (pred-ne-zone) doses does not compromise results while minimizing weight gain, diabetes and bone complications.”
Corticosteroids were the first anti-rejection drug used in transplant patients, dating back to the first transplant surgeries over 50 years ago.
Traditionally patients who have undergone organ transplantation have required life-long steroid treatments given in combination with other drugs that help suppress the body’s immune system and allow the transplanted organ to function properly.
However, the steroid treatment—given as the oral drug, prednisone—can cause serious side effects including cardiovascular disease, high cholesterol and blood pressure, weight gain, diabetes, bone weakness and cataracts.
The study also involved researchers from the University of Wisconsin; the University of Utah; the Methodist Hospital, Houston; and Weill Cornell Medical College and was funded by Astellas Pharma U.S., Inc.

Friday, 28 May 2010

Kidney transplant patients can benefit from abstinence

When certain immunosuppressive drugs are withdrawn after kidney transplantation, patients can experience prolonged survival and save a significant amount of money when compared to patients on these medications for life.
The finding was disclosed in a study that appeared in an issue of the Journal of the American Society Nephrology (JASN).
Sirolimus, in combination with steroids, is currently the only immunosuppressive treatment regimen that is approved for use when calcineurin inhibitors are withdrawn. Therefore, Dr. Earnshaw's group compared treatments containing sirolimus plus steroids versus treatments that maintained the use of calcineurin inhibitors.
The researchers' decision-analytic model, using data published in the literature and reported by the US transplant registry, assumed that within the first 12 months following transplant surgery, sirolimus plus steroid therapy is associated with a greater risk of kidney allograft rejection than regimens that continue to use calcineurin inhibitors. Other commonly used regimens include a calcineurin inhibitor such as cyclosporine or tacrolimus, plus mycophenolate mofetil and steroids. In this particular study, it was assumed that in the absence of induction therapy a total of 21.8% of patients taking sirolimus plus steroids experienced acute rejection within one year of transplantation, compared with 19.0% of patients taking cyclosporine plus mycophenolate mofetil and steroids, and 17.1% of patients taking tacrolimus plus mycophenolate mofetil and steroids.
However, it was revealed that overall, treatment with sirolimus plus steroids may be more efficacious and less costly than regimens that continued to use calcineurin inhibitors. Specifically, withdrawal of calcineurin inhibitors may prolong patients' lives and improve their kidney function.
Wyeth Pharmaceuticals in Collegeville, PA, provided funding for this analysis.